Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06173518 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 11 → 14 locations
  2. Study sites: 9 to 11
  3. Primary endpoints: details revised at 1 of 3 entries Study sites: 8 to 9 · Eligibility criteria expanded, about 11 words · Study description revised · 1 more Show 4 more changesShow less
    • Study sites: 8 to 9
    • Eligibility criteria expanded, about 11 words
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  4. Primary endpoints: 2 to 3 Eligibility criteria shortened, about 333 words · Secondary endpoints: 17 to 10 · Study description shortened, about 99 wordsv5 Show 3 more changesShow less
    • Eligibility criteria shortened, about 333 words
    • Secondary endpoints: 17 to 10
    • Study description shortened, about 99 words

    See this version in full on ClinicalTrials.gov ↗

  5. Primary endpoints: 3 to 2 Enrollment target: 24 to 30 · Study sites: 6 to 8 · Eligibility criteria expanded, about 94 words · 3 morev4 Show 6 more changesShow less
    • Enrollment target: 24 to 30
    • Study sites: 6 to 8
    • Eligibility criteria expanded, about 94 words
    • Secondary endpoints: 12 to 17
    • Study title revised
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 1 to 6 Eligibility criteria expanded, about 89 words · Secondary endpoints revised (12) · Study description revisedv3 Show 3 more changesShow less
    • Eligibility criteria expanded, about 89 words
    • Secondary endpoints revised (12)
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).
Trial Details
NCT Number NCT06173518
Lead Sponsor Autolus Limited
Conditions Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov